We recently published 10 Easy Double-Digit Gainers. Roivant Sciences Ltd. (NASDAQ:ROIV) was one of the best performers last ...
Hosted on MSN
Why Roivant Sciences Stock Was Slipping on Monday
The biotech published an earnings report that fell short of expectations. It whiffed on both the top and bottom lines. 10 stocks we like better than Roivant Sciences › Commercial-stage biotech Roivant ...
The average one-year price target for Roivant Sciences (NasdaqGS:ROIV) has been revised to $32.44 / share. This is an ...
Roivant Sciences stock: recent performance snapshot Roivant Sciences (ROIV) has drawn fresh attention after a strong recent run, with the share price at $25.82 and positive returns over the past week, ...
Pulmovant, a Roivant Sciences subsidiary, has completed enrollment in the Phase 2 PHocus trial of mosliciguat for pulmonary hypertension associated with interstitial lung disease. The PHocus study is ...
Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.
Tuesday's raiser was Leerink Partners prognosticator David Risinger. Well before market open, he added $1 to his Roivant price target for a new level of $18 per share. In doing so, he maintained his ...
Roivant Sciences (NASDAQ:ROIV) is gearing up to announce its quarterly earnings on Friday, 2026-02-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...
The biotech published an earnings report that fell short of expectations. It whiffed on both the top and bottom lines. Roivant reported that its revenue for the period was slightly under $2.2 billion, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results